Drugs / Deoxycholate Amphotericin B
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06525389 | Jul 2026 → Jul 2030 expected | penicilliosis | Duke University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deoxycholate Amphotericin B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525389 ↗ |
| Known as | DAmB | “Deoxycholate Amphotericin B (DAmB)” NCT06525389 ↗ |
| Route | Intravenous | “Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.” NCT06525389 ↗ |